Cogentix Medical (Cogentix Medical) Total Current Assets : $43.68 Mil (As of Dec. 2017)

View and export this data going back to 1992. Start your Free Trial

What is Cogentix Medical Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Cogentix Medical's total current assets for the quarter that ended in Dec. 2017 was $43.68 Mil.

Cogentix Medical Total Current Assets Historical Data

The historical data trend for Cogentix Medical's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cogentix Medical Total Current Assets Chart

Cogentix Medical Annual Data

Trend

Mar08

Mar09

Mar10

Mar11

Mar12

Mar13

Mar14

Mar15

Dec16

Dec17

Total Current Assets

Get a 7-Day Free Trial

9.85

9.70

22.14

37.52

43.68

Cogentix Medical Quarterly Data
	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17
Total Current Assets	Get a 7-Day Free Trial															37.52	36.68	39.87	41.58	43.68

Cogentix Medical Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Cogentix Medical's Total Current Assets for the fiscal year that ended in Dec. 2017 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	27.157	+	8.276	+	7.177	+	1.074
	=	43.68

Cogentix Medical's Total Current Assets for the quarter that ended in Dec. 2017 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	27.157	+	8.276	+	7.177	+	1.074
	=	43.68

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Cogentix Medical (NAS:CGNT) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Cogentix Medical's Liquidation Value for the quarter that ended in Dec. 2017 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	27.157	-	10.708	+	0.75 * 8.276	+	0.5 * 7.177
=	26.24

Cogentix Medical Total Current Assets Related Terms

Thank you for viewing the detailed overview of Cogentix Medical's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Cogentix Medical (Cogentix Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cogentix Medical Inc (NAS:CGNT) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

5420 Feltl Road, Minnetonka, MN, USA, 55343

Website

http://www.cogentixmedical.com

Cogentix Medical Inc is a medical device company. The company designs, develops, manufactures and markets a robust line of high-performance fiberoptic and video endoscopy products under the PrimeSight brand that is used across multiple surgical specialties in diagnostic and treatment procedures. Cogentix offers the Urgent PC Neuromodulation System, a device that delivers percutaneous tibial nerve stimulation (PTNS), for the office-based treatment of overactive bladder (OAB). It also develops Macroplastique an injectable, urethral bulking agent for the treatment of adult female stress urinary incontinence primarily resulting from intrinsic sphincter deficiency.

Executives

Nachum Shamir	director	12212 TECHNOLOGY BLVD, AUSTIN TX 78727
Brett Reynolds	officer: SVP, CFO, Treasurer	5000 W 36TH STREET, MINNEAPOLIS MN 55416
Kenneth A Samet	director	800 KING FARM BOULEVARD, 4TH FLOOR, ROCKVILLE MD 20850
Uri Geiger	director	221 LATHROP WAY, SUITE I, SACRAMENTO CA 95815
Accelmed Growth Partners, L.p.	10 percent owner	6 HACHOSHLIM STREET, 6TH FLOOR, HERZLIYA PITUACH L3 4672406
Accelmed Growth Partners Management Ltd.	10 percent owner	6 HACHOCHLIM STREET, 6TH FLOOR, HERZLIYA PITUACH L3 4672406
Accelmed Growth Partners (gp), L.p.	10 percent owner	6 HACHOCHLIM STREET, 6TH FLOOR, HERZLIYA PITUACH L3 4672406
Accelmed Growth Partners (agp) Ltd	10 percent owner	6 HACHOCHLIM STREET, 6TH FLOOR, HERZLIYA PITUACH L3 4672406
Cheryl Pegus	director	40 RAMLAND ROAD, ORANGEBURG CA 10962
Kenneth H Paulus	director	5420 FELTL ROAD, MINNETONKA MN 55343
Sven Wehrwein	director
Kevin H Roche	director
David W Anderson	director	519 LYNMERE ROAD, BRYN MAWR PA 19010